Prosigna® prognostic breast cancer test
An innovative genomic test that evaluates the expression of 50 tumour genes and helps estimate the risk of breast cancer recurrence over the next 10 years. The test supports selection of the most accurate individual treatment plan – balancing treatment effectiveness with preservation of quality of life.
Treatment starts with accurate risk assessment
Breast cancer is the most common cancer among women in Lithuania and worldwide. While treatment options continue to improve, one of the greatest challenges remains accurately estimating recurrence risk and choosing the most effective individual therapy.
The Prosigna® test analyses tumour gene expression to determine long-term recurrence probability and helps tailor treatment so that it is strong enough – but not excessive.
How does Prosigna® help individualise breast cancer treatment?
Prosigna® is an advanced genomic test that analyses expression of 50 tumour genes and evaluates breast cancer recurrence risk over a 10-year period. The test is based on an RNA analysis method and enables precise assignment of a patient to an appropriate risk group, supporting evidence-based decisions about treatment intensity.
Evaluates expression of 50 genes associated with breast cancer progression
Determines the tumour molecular subtype: Luminal A, Luminal B, HER2-enriched, or Basal-like
Calculates recurrence risk on a 100-point scale
Incorporates clinical factors such as age, tumour size, and lymph node involvement
Helps avoid overtreatment or undertreatment
Data-driven treatment – no doubts
Prosigna® helps clinicians make individualised decisions based on tumour biology, and helps patients avoid too much – or too little – treatment. The test provides greater clarity, supports avoiding unnecessary chemotherapy, or ensures it is prescribed in time – when it is truly needed.
Accurate recurrence risk assessment
Based on 50-gene expression, tumour type, size, and lymph node status, the test estimates the likelihood of recurrence over the next 10 years.
Evidence-based chemotherapy decisions
Helps determine whether combined treatment (hormone therapy + chemotherapy) is necessary, or whether a less intensive approach may be sufficient.
Science-based recommendation
An algorithm validated in thousands of cases provides a standardised, clinically reliable decision – without relying on guesswork.
Improved quality of life
Many women who received Prosigna® results avoided more aggressive treatment, maintained better wellbeing, and experienced fewer side effects.
When and for whom is the test recommended?
For patients diagnosed with stage I or II breast cancer
Intended for early-stage (I–II) HR+ / HER2– breast cancer to support personalised treatment.
When chemotherapy is being considered
Helps assess whether combined therapy (chemotherapy + hormone therapy) is needed or whether hormone therapy alone may be sufficient.
For patients seeking a more confident, evidence-based treatment decision
Results help reduce uncertainty about treatment benefit and avoid unnecessary therapy.
When recommended by the Multidisciplinary Team
The test may be prescribed by a multidisciplinary specialist team and can be reimbursed in Lithuania from Compulsory Health Insurance Fund if the case meets required criteria.
Prosigna® reliability: accuracy and quality metrics
Prosigna® is a clinically validated genomic test supported by thousands of real-world breast cancer cases, ensuring accurate and objective recurrence risk assessment. It enables earlier prediction of disease course and supports personalised treatment.
Standardised RNA algorithm analysing 50-gene expression
100-point scale to precisely estimate 10-year recurrence risk
Accurate assessment of breast cancer recurrence risk
Take the Prosigna® test and receive a clear, science-based treatment plan.
For Specialists
All key information in one place – from the genes analysed to accuracy and clinical value. This section is intended for specialists who want a detailed understanding of the test rationale, structure, and practical applications.
Prosigna® is indicated for patients diagnosed with stage I–II HR+/HER2– breast cancer. The test may be prescribed by a multidisciplinary specialist team, and since February 2022 it may be reimbursed in Lithuania from the Compulsory Health Insurance Fund.
Prosigna® is a second-generation molecular test that evaluates expression of 50 tumour genes and calculates 10-year recurrence risk on a 100-point scale. It meaningfully complements pathology and immunohistochemistry data for treatment decision-making.
The report includes the tumour molecular subtype (Luminal A, Luminal B, HER2-enriched, or Basal-like), a numerical risk score, and other clinically important information (patient age, tumour size, lymph node involvement), helping assign the patient to the appropriate risk group.
The Prosigna® algorithm has been clinically validated in thousands of real-world breast cancer cases. Assessment is based on gene-expression profiling and tumour molecular subtype, as well as tumour size and lymph node involvement, ensuring an individualised prognosis.
According to data presented by Prof. Bjørn Naume, Prosigna® results changed the treatment decision in 28% of cases. Most changes favoured less aggressive therapy, while for some patients more intensive treatment was recommended.
An objective RNA-based test helps harmonise treatment protocols across healthcare institutions. This reduces overtreatment and improves decision accuracy in clinical practice at different levels.
